ETBOND TECHNOLOGY (TM) Patented technology that advances "The Fundamentals of Immunology" Drug Development Stage: PRE-IND Number assigned by FDA for 1. ET 007 SWF to contain the spread of disease. Human safety record available. 2. ET 007 SWF to reduce mortality in patients hospitalized in Intensive Care Units. Human safety record available. 3.
ET 007 SWF to assist global vaccine developers to improve their safety
and efficacy. ETBOND TECHNOLOGY is Advanced to near completion of
Pre-clinical development in following list of illnesses. 1. Endocrinology, Diabetes and Metabolism: Cure of diabetes and its complications 2. Ophthalmology: Age-related Macular Diseases (AMD-Blindness) 3. Oncology: Cancer Metastasis 4. Nephrology: Treatment of Acute renal failure due to Atypical Hemolytic Uremia Syndrome (aHUS)
ET007SWF
1.
H1N1 Influenza A, 2009 pandemic is a Global Health Problem. Since its
first appearance in April 2009, it has spread globally infecting
millions of patients. 2. Since this is a new virus, there is no
preformed immunity in people. This allows virus to multiply rapidly
contributing to the spread of the disease 3. Influenza A
relentlessly exploits the working of early human defense system. In
immune suppressed individuals it may cause death due to pneumonia and
acute respiratory distress syndrome. 4. Currently available Drugs
are ineffective. Technology advances are of supportive and of limited
value in preventing death toll. ET 007 is an antiviral and
anti-inflammatory compound. It "Advances the Fundamentals of
Immunology". It safely neutralizes Influenza A and its immune
interaction. It is a globally available drug in following list of
countries 1)USA 2)Canada 3)UK 4)Switzerland 5)Spain 6)France 7)Germany 8)Ireland 9)Italy 10)South Africa 11)Netherlands 12)Belgium 13)Austria 14)Australia 15)Sweden
In
appropriate formulation it can be used for prophylactic applications to
block entry and fusion of virus as well as to inhibit inflammation in
lungs.
